Creating RNA treatments for rare brain disorders
Developing RNA therapeutics for rare neurodevelopmental disorders
This study is exploring new RNA-based treatments for rare brain disorders caused by single gene changes, aiming to help those affected by these conditions by restoring normal gene function and offering hope for better care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dayi Therapeutics, INC. NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11239933 on NIH RePORTER |
What this research studies
This research focuses on developing RNA-based therapies to treat rare neurodevelopmental disorders caused by single gene mutations. These conditions, while individually rare, affect a significant portion of the population and often have no existing treatments. The approach involves using antisense oligonucleotides (ASOs) to modify gene expression and restore normal protein function. By targeting specific genes associated with severe developmental disabilities, the research aims to provide a new therapeutic option for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rare neurodevelopmental disorders linked to specific gene mutations.
Not a fit: Patients with neurodevelopmental disorders that are not linked to single gene mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for patients suffering from rare neurodevelopmental disorders, improving their quality of life.
How similar studies have performed: Other research has shown promise in using RNA-based therapies for genetic disorders, indicating potential success for this novel approach.
Where this research is happening
College Station, United States
- Dayi Therapeutics, INC. — College Station, United States (Active)
Researchers
- Principal investigator: Lotti, Francesco — Dayi Therapeutics, INC.
- Study coordinator: Lotti, Francesco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.